By Kamal Choudhury Oct 22 (Reuters) – Moderna's shares sank over 25% on Thursday as late-stage trial data for its personalized melanoma vaccine, developed with Merck, triggered what analysts called a
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
By Jacob Bogage and Kanishka Singh WASHINGTON, Oct 22 (Reuters) - Donald Trump said on…
BRADESCO Q3 CONSOLIDATED LOAN BOOK 1.15 TRLN REAIS (The article has been published through a…
VIDEO SHOWS: ARGENTINIAN SOCCER START LIONEL MESSI ADDRESSING SCHOOL COMMUNITY / SOUNDBITES FROM MESSI /…
Oct 22 (Reuters) - SpaceX disclosed on Thursday its potential merger with Tesla will require…
Oct 22 (Reuters) - Major US banks have been blocking third-party AI agents from operating…
Oct 22 (OPTA) - Results and fixtures for the UEFA Europa League on Thursday (start…